Observation and treatment in DDX41-mutated acute myeloid leukemia and myelodysplastic syndrome |
Apr 2023 |
Blood Cancer |
Myelodysplastic Syndromes (MDS) |
Raising the bar for lower-risk myelodysplastic syndromes |
Apr 2023 |
Leukemia & Lymphoma |
Myelodysplastic Syndromes (MDS) |
Alemtuzumab in relapsed immune severe aplastic anemia: Long-term results of a phase II study |
Apr 2023 |
American Journal of Hematology |
Aplastic Anemia |
Time without transfusion reliance: a novel patient-centric metric for new therapies in myelodysplastic syndromes |
Apr 2023 |
Haematologica |
Myelodysplastic Syndromes (MDS) |
T cell dysfunctions in myelodysplastic syndromes |
Jan 2023 |
Blood |
Myelodysplastic Syndromes (MDS) |
Predicting response of severe aplastic anemia to immunosuppression combined with eltrombopag |
Apr 2021 |
Haematologica |
Aplastic Anemia |
Palliative Medicine in Myelodysplastic Syndromes: Patients and Caregivers - A Qualitative Study |
Apr 2021 |
BMJ Supportive & Palliative Care |
Myelodysplastic Syndromes (MDS) |
Eltrombopag in children with severe aplastic anemia |
Apr 2021 |
Pediatric Blood & Cancer |
Aplastic Anemia, Pediatric |
Iron overload after complement inhibitor treatment of Paroxysmal Nocturnal Hemoglobinuria |
Apr 2021 |
American Journal of Hematology |
Paroxysmal Nocturnal Hemoglobinuria (PNH) |
Traipsing Through Muddy Waters: A Critical Review of the Myelodysplastic Syndrome/Myeloproliferative Neoplasm (MDS/MPN) Overlap Syndromes |
Apr 2021 |
Hematology/oncology clinics of North America |
Myelodysplastic Syndromes (MDS), Myeloproliferative Neoplasms (MPN) |